Evaluating the investigational drug landscape for ESR1-mutated, estrogen receptor positive, HER2 negative metastatic breast cancer [0.03%]
评估ESR1突变型、雌激素受体阳性、HER2阴性转移性乳腺癌的在研药物格局
Marie Kroemer,Morgane Lopez,Laura Mansi et al.
Marie Kroemer et al.
Introduction: Estrogen receptor positive, HER2 negative (ER+/HER2-) metastatic breast cancer represents a major therapeutic challenge due to the frequent development of endocrine resistance. This review focuses on ESR1 mu...
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges [0.03%]
达依加巴汀和亚型选择性GABAA调制：药理学、临床开发及转化挑战
Luigi Francesco Iannone,Marina Romozzi,Luca Pani et al.
Luigi Francesco Iannone et al.
Introduction: Darigabat is a selective γ-aminobutyric acid type A (GABA-A) receptor positive allosteric modulator targeting α2, α3, and α5 subunits, developed to preserve anxiolytic and anticonvulsant effects while re...
Safety, tolerability, and pharmacokinetics of HL-300, a novel topical pan-JAK inhibitor, in healthy Chinese adults: a first-in-human, randomized, double-blind, placebo-controlled phase I trial [0.03%]
HL-300在健康中国成年人中的安全性和耐受性及其药代动力学：一项首次人体、随机、双盲和安慰剂对照的Ⅰ期临床试验
Hui Qiu,Xingfei Zhang,Jie Huang et al.
Hui Qiu et al.
Introduction: HL-300 is a novel topical pan-JAK inhibitor targeting JAK1, JAK2, JAK3, and TYK2 for atopic dermatitis (AD). This first-in-human study evaluated its safety, tolerability, and pharmacokinetics (PK) in healthy...
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis [0.03%]
新型BET抑制剂对骨髓纤维化治疗的影响
Matteo Bellia,Clara Deambrogi,Abdurraouf Mokhtar Mahmoud et al.
Matteo Bellia et al.
Introduction: Myelofibrosis (MF) is a clonal myeloproliferative neoplasm driven by dysregulated JAK-STAT signaling and epigenetic alterations, characterized by chronic inflammation, marrow fibrosis, and limited disease-mo...
The journey of targeted drug conjugates in solid tumors: moving beyond antibody drug conjugates [0.03%]
实体瘤靶向药物偶联物的进展：抗体药物偶联物之外的世界
Stephen Walsh,Francesca Wood,Leslie R DeMars et al.
Stephen Walsh et al.
Introduction: Antibody drug conjugates (ADCs) selectively deliver cytotoxins to tumor cells using highly specific monoclonal antibodies. While ADCs are a standard treatment paradigm in oncology, safety- and efficacy-relat...
SOT201: cis-acting PD-1/IL-15 mutein-based immunocytokine under investigational study in solid tumors [0.03%]
SOT201：针对实体瘤研究中的基于cis-acting PD-1 / IL-15 基因突变免疫细胞因子药物
Vladyslav Mazhara,Irfan Baki Kilic,Irena Adkins et al.
Vladyslav Mazhara et al.
Introduction: The systemic administration of cytokines is constrained by their pleiotropic activity, dose-dependent toxicities, and short serum half-life, limiting their therapeutic window in cancer treatment. To overcome...
Alpha-1 antitrypsin: therapeutic applications beyond serine protease inhibition [0.03%]
α1抗胰蛋白酶：超出现有丝氨酸蛋白酶抑制作用的治疗应用
Martina Toldo,Trushaben Patel,Michele Golino et al.
Martina Toldo et al.
Introduction: Alpha-1 antitrypsin (AAT) is an acute-phase glycoprotein belonging to the serine protease inhibitor (SERPIN) superfamily. An advanced understanding of functional and post-translational modifications highligh...
A novel sequential ketamine and D-Cycloserine/lurasidone therapy for bipolar depression with acute suicidal ideation [0.03%]
一项用于伴有急性自杀意念的双相情感障碍患者的新型氯胺酮联合D-环丝氨酸/鲁拉西 tone治疗法研究
Mina Takahashi,Richard C Shelton
Mina Takahashi
Introduction: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the ...
Sinem Nihal Esatoglu,Yesim Ozguler,Gulen Hatemi
Sinem Nihal Esatoglu
Introduction: Behçet syndrome (BS) is a multisystem variable-vessel vasculitis characterized by recurrent mucocutaneous manifestations and severe organ involvement affecting the eyes, blood vessels, nervous system, and g...
GV1001: repurposing a telomerase-derived peptide for neurological therapeutics [0.03%]
GV1001：将端粒酶衍生的肽重新用于神经治疗药物
Kyoungho Suk,Won-Ha Lee
Kyoungho Suk
Introduction: Neurodegenerative and demyelinating diseases represent major unmet medical needs, with existing therapeutics demonstrating limited efficacy and significant safety concerns. Drug repurposing offers accelerate...